Skip to main content

Table 4 Univariate analysis of potential prognostic factors for overall Survival (n = 35 patients) following primary tumor resection and liver directed therapy (LDT) , respectively

From: The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy

   Follow-Up Liver-directed therapy   Follow-Up Primary Tumor Resection  
Variables n Median Time (months) with IQR p-value Median Time (months) with IQR p-value
Gender      
 Male 24 42 (21–98) 0.7 96 (34–130) 0.4
 Female 11 37 (12–68)   62 (63–126)  
Targeted therapy      
 TKI+ 16 98 (57–133) 0.032 151 (126–202) 0.003
 TKI− 19 40 (12–64)   61 (25–103)  
ECOG      
 0 29 57 (37–98) 0.001 103 (79–151) <0.001
 > 1 6 12 (9–18)   15 (13–34)  
Age      
 < 65 years 18 64 (35–98) 0.07 96 (34–151) 0.31
 > 65 years 17 40 (12–57)   63 (79–126)  
Tumor distribution      
 unilobular 28 98 (21–76) 0.911 126 (25–151) 0.8
 multilobular 7 42 (12–98)   86 (54–126)  
Synchronous Extrahepatic Disease      
 Yes 7 21 (9–37) 0.312 63 (54–126) 0.727
 No 28 47 (28–98)   86 (61–159)  
Liver metastasis Timing      
 Synchronous 6 9 (8–12) 0.006 15 (8–63) 0.006
 Metachronous 29 47 (28–98)   96 (54–151)  
Tumor size, cm      
 < 45 mm 21 98 (28–133) 0.007 103 (86–151) 0.007
 > 45 mm 14 37 (12–57)   63 (18–85)  
Resection margin      
 Radical resection (R0) 30 47 (21–98) 0.013 96 (48–151) 0.041
 Irradical resection (R1/R2) 5 9 (8–28)   86 (13–92)  
Number of metastases      
 Solitary 22 64 (12–98) 0.850 85 (54–153) 0.990
 Multiple 13 42 (21–76)   116 (34–130)  
T-stage      
 T1/T2 16 47 (37–98) 0.062 126 (62–151) 0.257
 T3/T4 19 40 (12–64)   85 (54–103)  
Grading of RCC      
 Low (G1/G2) 24 47 (37–133) 0.543 116 (63–126) 0.501
 High (G3/G4) 11 28 (9–98)   85 (51–151)  
Disease-free intervall      
 < 12 months 17 13 (9–42) 0.002 79 (18–96) 0.2
 > 12 months 18 64 (42–98)   103 (62–151)  
Histology      
 Clear cell 25 47 (40–98) 0.821 96 (51–151) 0.498
 Non clear cell 10 42 (18–132)   85 (54–116)  
Surgical complications      
 Yes 10 28 (21–40) 0.996 85 (49–118) 0.104
 No 25 47 (13–98)   151 (54–202)  
  1. TKI Tyrosinkinase InhibitorTherapy, ECOG Eastern Cooperative Oncology Group
  2. The bold data specifies a staticial significance p-values < 0.05